• Samsung Electronics' total securities holding in Samsung Biologics rose to 32.05% from 31.22% on October 19, 2026.
• The increase reflected receipt of 567,503 subscription rights certificates through a shareholder rights offering, bringing total securities held to 15,017,447.
• Its shareholding remained unchanged at 14,449,944 shares, or 31.22%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung Biologics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261023000467), on October 23, 2026, and is solely responsible for the information contained therein.